A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors-Reference-Cited by-同舟云学术

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

Published:2017-03-06 Issue:15 Volume:23 Page:4095-4106
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kristeleit Rebecca,Shapiro Geoffrey I.,Burris Howard A.,Oza Amit M.,LoRusso Patricia,Patel Manish R.,Domchek Susan M.,Balmaña Judith,Drew Yvette,Chen Lee-may,Safra Tamar,Montes Ana,Giordano Heidi,Maloney Lara,Goble Sandra,Isaacson Jeff,Xiao Jim,Borrow Jen,Rolfe Lindsey,Shapira-Frommer Ronnie

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 211 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis;Taiwanese Journal of Obstetrics and Gynecology;2024-09

2. Inactivation of VRK1 sensitizes ovarian cancer to PARP inhibition through regulating DNA-PK stability;Experimental Cell Research;2024-05

3. Identification of estrogen response-associated STRA6+ granulosa cells within high-grade serous ovarian carcinoma by single-cell sequencing;Heliyon;2024-03

4. Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer—Genetic Instability and Clinical Implications;Cells;2024-02-15

5. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer;Critical Reviews in Oncology/Hematology;2024-02